SEC v. Bruce Cameron Conway, No. LR-26370, Northern District of Texas (Aug. 11, 2025) — Press Release
raw: Bruce Cameron Conway
Bruce Cameron Conway, No. 3:25-cv-02101 (Aug. 11, 2025)
summary
Bruce Cameron Conway was charged by the SEC for insider trading ahead of a 2020 merger involving Cancer Genetics, Inc., resulting in $160,000 in profits.
paragraph
The SEC charged Dallas resident Bruce Cameron Conway with violating antifraud provisions of the Securities Exchange Act of 1934. Conway allegedly used non-public information to purchase Cancer Genetics shares across fifteen accounts, yielding approximately $160,000 in profits. The litigation seeks injunctive relief, disgorgement with prejudgment interest, and civil penalties.
narrative
The SEC filed charges against Bruce Cameron Conway for insider trading related to the 2020 merger of Cancer Genetics, Inc. and a private biotechnology company. In July 2020, Conway learned of the merger through a private investment and subsequently purchased shares across fifteen accounts belonging to himself, family members, and family trusts. Following the public merger announcement on August 24, 2020, Cancer Genetics stock surged by 215 percent, generating $160,000 in profits for Conway. The SEC complaint alleges violations of Section 10(b) and Rule 10b-5 of the Securities Exchange Act of 1934. The agency is seeking injunctive relief, disgorgement of profits with prejudgment interest, and civil penalties in the Northern District of Texas. The investigation was conducted by the SEC’s Denver Regional Office with assistance from FINRA.
Classified insider-trading(confidence 100%). EDGAR detection: forms 4/3/5/144· recall 81% / precision 19%. detection rule →
Parties
Securities and Exchange CommissionBruce Cameron Conway
Keywords
conwaysecurities exchangecancer geneticsbiotechnology companysecbruce cameroncameron conwayexchange commissionsecuritiesexchangeaugustcancergeneticsbiotechnologycompany
Exhibits & Attached Documents (1)
Extracted insights
Dollar amounts 1
- $160K $160,000 $100K–$1M
Entities 8
- person bruce cameron conway
- person cancer genetics stock
- person john dwyer
- agency the assistance of the financial industry regulatory authority
- agency United States Securities And Exchange Commission
- agency united states securities and exchange commission complaint
- agency united states securities and exchange commission investigation
- agency united states securities and exchange commission litigation
Triples 11
- United States Securities And Exchange Commission filed charges against Bruce Cameron Conway
- Bruce Cameron Conway learned the biotechnology company planned to merge with Cancer Genetics
- Bruce Cameron Conway purchased Cancer Genetics shares in fifteen accounts belonging to him, various family members, and family-owned trusts
- Bruce Cameron Conway purchased shares in a personal account the same day he invested in the biotechnology company
- Cancer Genetics Stock rose by 215 percent after the merger announcement on August 24, 2020
- United States Securities And Exchange Commission Complaint charges Bruce Cameron Conway with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5
- United States Securities And Exchange Commission Investigation was conducted by John Dwyer
- United States Securities And Exchange Commission Investigation was supervised by Kimberly Frederick and Nicholas Heinke
- United States Securities And Exchange Commission Litigation will be led by John Dwyer and Jodanna Haskins
- United States Securities And Exchange Commission Litigation will be supervised by Gregory a. Kasper
- United States Securities And Exchange Commission appreciates the assistance of the Financial Industry Regulatory Authority
PDF (from attached: complaint)
Text layers
Extracted body text (1,855c)
U.S. SECURITIES AND EXCHANGE COMMISSION Litigation Release No. 26370 / August 11, 2025 Securities and Exchange Commission v. Conway, No. 3:25-cv-02101 (N.D. Tex. filed Aug. 7, 2025) SEC Charges Texas Resident with Insider Trading On August 7, 2025, the Securities and Exchange Commission filed charges against Bruce Cameron Conway, a resident of Dallas, Texas, for insider trading in advance of the August 24, 2020 announcement that Cancer Genetics, Inc. would merge with a privately held biotechnology company. According to the SEC’s complaint, in July 2020, in connection with an investment into a privately-held biotechnology company, Conway learned that the biotechnology company planned to merge with Cancer Genetics. The complaint further alleges Conway purchased Cancer Genetics shares in fifteen accounts belonging to him, various family members, and family-owned trusts, including purchasing shares in a personal account the same day he invested in the biotechnology company. On August 24, 2020, the merger was publicly announced, and the price of Cancer Genetics stock rose by 215 percent from the previous day’s closing price, resulting in trading profits to Conway of approximately $160,000. The SEC’s complaint, filed in federal court in the Northern District of Texas, charges Conway with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and seeks injunctive relief, disgorgement with prejudgment interest, and civil penalties. The SEC’s investigation was conducted by John Dwyer and supervised by Kimberly Frederick and Nicholas Heinke, all of the SEC’s Denver Regional Office. The SEC’s litigation will be led by John Dwyer and Jodanna Haskins, under the supervision of Gregory A. Kasper. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.
OCR text (1,855c · html-text · 99% conf)
U.S. SECURITIES AND EXCHANGE COMMISSION Litigation Release No. 26370 / August 11, 2025 Securities and Exchange Commission v. Conway, No. 3:25-cv-02101 (N.D. Tex. filed Aug. 7, 2025) SEC Charges Texas Resident with Insider Trading On August 7, 2025, the Securities and Exchange Commission filed charges against Bruce Cameron Conway, a resident of Dallas, Texas, for insider trading in advance of the August 24, 2020 announcement that Cancer Genetics, Inc. would merge with a privately held biotechnology company. According to the SEC’s complaint, in July 2020, in connection with an investment into a privately-held biotechnology company, Conway learned that the biotechnology company planned to merge with Cancer Genetics. The complaint further alleges Conway purchased Cancer Genetics shares in fifteen accounts belonging to him, various family members, and family-owned trusts, including purchasing shares in a personal account the same day he invested in the biotechnology company. On August 24, 2020, the merger was publicly announced, and the price of Cancer Genetics stock rose by 215 percent from the previous day’s closing price, resulting in trading profits to Conway of approximately $160,000. The SEC’s complaint, filed in federal court in the Northern District of Texas, charges Conway with violating the antifraud provisions of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder and seeks injunctive relief, disgorgement with prejudgment interest, and civil penalties. The SEC’s investigation was conducted by John Dwyer and supervised by Kimberly Frederick and Nicholas Heinke, all of the SEC’s Denver Regional Office. The SEC’s litigation will be led by John Dwyer and Jodanna Haskins, under the supervision of Gregory A. Kasper. The SEC appreciates the assistance of the Financial Industry Regulatory Authority.